15:22:05 EDT Fri 14 Jun 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:COEP - COEPTIS THERAPEUTICS HOLDINGS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
COEP - Q0.20.3201·0.3350.10.3204+0.01284.2162.5441290.3076  0.3204  0.30011.87  0.230315:01:38May 3015 min RT 2¢

Recent Trades - Last 10 of 129
Time ETExPriceChangeVolume
15:01:38Q0.3210.01320
15:00:46Q0.32260.014647
15:00:38Q0.32040.01281,000
14:58:02Q0.320.0124100
14:56:55Q0.31660.009100
14:56:42Q0.31660.009100
14:54:52Q0.320.0124503
14:50:57Q0.31660.009300
14:43:43Q0.320.01250
14:37:49Q0.31660.008652

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-30 08:47U:COEPNews ReleaseCoeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting
2024-05-08 08:47U:COEPNews ReleaseCoeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024
2024-05-02 08:47U:COEPNews ReleaseCoeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
2024-04-02 08:47U:COEPNews ReleaseCoeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award
2024-02-26 09:00U:COEPNews ReleaseCoeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
2024-02-07 07:30U:COEPNews ReleaseCoeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
2024-01-04 07:30U:COEPNews ReleaseCoeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024
2023-10-31 09:01U:COEPNews ReleaseCoeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023
2023-10-24 08:30U:COEPNews ReleaseCoeptis Therapeutics Announces $2 Million Private Placement
2023-10-11 07:30U:COEPNews ReleaseCoeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology
2023-10-09 09:15U:COEPNews ReleaseCoeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies
2023-10-04 07:30U:COEPNews ReleaseCoeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting
2023-09-27 07:30U:COEPNews ReleaseCoeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa
2023-09-14 07:30U:COEPNews ReleaseCoeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection
2023-09-11 07:30U:COEPNews ReleaseCoeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment
2023-08-30 13:00U:COEPNews ReleaseCoeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer
2023-08-17 07:30U:COEPNews ReleaseCoeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics
2023-08-01 08:00U:COEPNews ReleaseCoeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic
2023-06-16 16:00U:COEPNews ReleaseCoeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering